Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
Substantial
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial.
Clinical Added Value
no clinical added value
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults.
Listen
